SCHEMBL5899407

SCHEMBL5899407

COCc1cc(C(=O)C=C(O)c2nc[nH]n2)cn1Cc1ccncc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.39
MAPK10 P53779 1/20 0.39
BRD4 O60885 2/20 0.33
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31
MAPK1 P28482 1/20 0.31
CCNC P24863 1/20 0.30
CDK8 P49336 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
SLC16A3 O15427 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678065 0.91 ALDH1A1 (0.35) MAPK10BRD4NPC1RAB9AALDH1A1
SCHEMBL4677748 0.89 ALKBH1 (0.35) USP2MAPK10RAB9AALDH1A1MAPK1
SCHEMBL4678417 0.86 USP2 (0.38) USP2MAPK10BRD4NPC1RAB9A
SCHEMBL4672731 0.86 USP2 (0.37) USP2MAPK10BRD4ALDH1A1CYP1A2
SCHEMBL4673403 0.85 BRD4 (0.35) BRD4ALDH1A1TSHRMAPK1MEN1
SCHEMBL4672821 0.84 USP2 (0.37) USP2MAPK10BRD4ALDH1A1CCNC
SCHEMBL4677108 0.81 MAPK10 (0.38) USP2MAPK10ALDH1A1MAPK1CCNC
SCHEMBL5899342 0.81 MAPK10 (0.38) USP2MAPK10BRD4ALDH1A1CCNC
SCHEMBL4671392 0.81 CCNC (0.39) USP2MAPK10ALDH1A1CCNCCDK8
SCHEMBL4671193 0.80 USP2 (0.39) USP2MAPK10BRD4ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 USP2 3545/4885MAPK10 4133/4885BRD4 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.